Flibanserin

Suppliers

Names

[ Name ]:
Flibanserin

[Synonym ]:
Ectris
1,3-Dihydro-1-(2-(4-(3-(trifluoromethyl)phenyl)-1-piperazinyl)ethyl)-2H-benzimidazol-2-one
Addyi
BIMT-17
Bimt 17
2H-Benzimidazol-2-one, 1,3-dihydro-1-[2-[4-[3-(trifluoromethyl)phenyl]-1-piperazinyl]ethyl]-
BIMT-17-BS
Flibanserin
3-[2-[4-[4-(trifluoromethyl)phenyl]piperazin-1-yl]ethyl]-1H-benzimidazol-2-one
1-(2-(4-(3-trifluoromethylphenyl)piperazin-1-yl)ethyl)benzimidazol(1H)-2-one
1-(2-{4-[3-(Trifluoromethyl)phenyl]-1-piperazinyl}ethyl)-1,3-dihydro-2H-benzimidazol-2-one
1-(2-{4-[3-(Trifluoromethyl)phenyl]piperazin-1-yl}ethyl)-1,3-dihydro-2H-benzimidazol-2-one

Chemical & Physical Properties

[ Density]:
1.292 g/cm3

[ Molecular Formula ]:
C₂₀H₂₁F₃N₄O

[ Molecular Weight ]:
390.40200

[ Exact Mass ]:
390.16700

[ PSA ]:
44.27000

[ LogP ]:
3.17350

[ Appearance of Characters ]:
white to beige

[ Index of Refraction ]:
1.566

[ Storage condition ]:
2-8°C

[ Water Solubility ]:
DMSO: soluble10mg/mL, clear

Safety Information

[ Symbol ]:

GHS06

[ Signal Word ]:
Danger

[ Hazard Statements ]:
H301-H315-H319-H335

[ Precautionary Statements ]:
P261-P301 + P310-P305 + P351 + P338

[ Hazard Codes ]:
T

[ Risk Phrases ]:
25-36/37/38

[ Safety Phrases ]:
26-45

[ RIDADR ]:
UN 2811 6.1 / PGIII

Articles

Continued efficacy and safety of flibanserin in premenopausal women with Hypoactive Sexual Desire Disorder (HSDD): results from a randomized withdrawal trial.

J. Sex. Med. 8(11) , 3160-72, (2011)

Flibanserin is a 5-HT(1A) agonist/5-HT(2A) antagonist that has been shown to increase sexual desire and reduce distress in premenopausal women with Hypoactive Sexual Desire Disorder (HSDD).To assess t...

Open-label extension study of flibanserin in women with hypoactive sexual desire disorder.

J. Sex. Med. 9(12) , 3180-8, (2012)

Hypoactive Sexual Desire Disorder (HSDD) is a common form of Female Sexual Dysfunction characterized by low sexual desire that causes distress or interpersonal difficulty.This 52-week open-label exten...

Satisfying sexual events as outcome measures in clinical trial of female sexual dysfunction.

J. Sex. Med. 8(12) , 3262-70, (2011)

Assessing the sexual response in women with female sexual dysfunctions (FSDs) in clinical trials remains difficult. Part of the challenge is the development of meaningful and valid end points that cap...